The Food and Drug Administration on Monday rejected Akcea Therapeutics’ application to market Waylivra, its drug for familial chylomicronemia syndrome, in the United States.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,